masitinib
Sign in to saveAlso known as AB-1010, AB1010, Masican® (proposed trade name), AB 1010
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumours in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. Masitinib has been studied for several human conditions including melanoma, multiple myeloma, gastrointestinal cancer, pancreatic cancer, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis, mastocytosis, amyotrophic lateral sclerosis, and COVID-19.
Wikidata facts
- Mass
- 498.220181
Show 4 more facts
- chemical formula
- C₂₈H₃₀N₆OS
- canonical SMILES
- CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5
- World Health Organisation international non-proprietary name
- masitinib
- Commons category
- Masitinib
via Wikidata · CC0
~4 min read
Article
4 sectionsContents
- Mechanism of action
- Society and culture
- Legal status
- References
{{Drugbox | IUPAC_name = 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide | image = Masitinib structure.svg | image_class = skin-invert-image | width = 250
| tradename = Masivet, Kinavet | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_category = | routes_of_administration = | ATC_prefix = L01 | ATC_suffix = EX06 | ATC_supplemental =
Available in 9 languages
via Wikidata sitelinks · CC0